Page 107 - NobleCon21

Jupiter Neurosciences, Inc.

SELECTED FINANCIAL ITEMS JUNS
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit (0.20) (0.47) (0.76) (0.82) (2.24)
Gross Margin NM NM NM NM NM
EBIT (1.46) (1.54) (2.26) (2.30) (7.56)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (1.53) (1.53) (2.25) (2.29) (7.60)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 6.20 4.96 3.97 2.58 2.58
Cash & Short Term Investments 3.77 2.71 1.88 0.72 0.72
% of Assets 61% 55% 47% 28% 28%
Current Assets -Total 4.65 3.61 2.82 1.63 1.63
% of Assets 75% 73% 71% 63% 63%
Total Liabilities 2.03 1.90 2.63 2.52 2.52
% of Assets 33% 38% 66% 98% 98%
Current Liabilities - Total 2.01 1.89 2.63 2.52 2.52
% of Assets 32% 38% 66% 98% 98%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 4.17 3.06 1.34 0.06 0.06
% of Assets 67% 62% 34% 2% 2%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (3.70) (1.06) (0.83) (1.15) (6.74)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing 7.47 NA NA NA 7.47

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference